

# Clinical Trial Supplies - Company Evaluation Report, 2025

<https://marketpublishers.com/r/CCA5A035E715EN.html>

Date: August 2025

Pages: 108

Price: US\$ 2,650.00 (Single User License)

ID: CCA5A035E715EN

## Abstracts

The Clinical Trial Supplies Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Clinical Trial Supplies. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. MarketsandMarkets 360 Quadrants evaluated over 120 companies, of which the Top 17 Clinical Trial Supplies Companies were categorized and recognized as the quadrant leaders.

The clinical trial supplies market is experiencing significant growth, driven by the increasing complexity of clinical trials, the rise in biologics and personalized medicine, and the globalization of clinical research. To manage costs, ensure regulatory compliance, and improve logistical efficiency, pharmaceutical and biotechnology companies are increasingly outsourcing supply chain operations to specialized service providers. Key innovations such as temperature-controlled packaging, direct-to-patient (DTP) delivery models, and the rise of decentralized clinical trials are accelerating demand for advanced supply chain solutions. The growing adoption of biologics, as well as cell and gene therapies, has further increased the need for robust cold chain logistics, real-time temperature monitoring, and cryogenic storage capabilities.

Digital transformation is also reshaping clinical trial supply management. AI-powered demand forecasting, blockchain-enabled transparency, and cloud-based inventory systems are enhancing operational efficiency and data integrity. As a result, pharmaceutical and biotech firms are partnering more frequently with Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) to access integrated, end-to-end clinical trial supply solutions—further fueling market expansion.

The 360 Quadrant maps the Clinical Trial Supplies companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Clinical Trial Supplies quadrant. The top criteria for product footprint evaluation included Service (logistics & distribution, storage & retention, packaging, labeling and blinding, manufacturing, comparator sourcing and other services) phase (Phase III, Phase II, Phase I, Phase IV, and Phase BA/BE) type (small molecules, biologics, and medical devices) therapeutic area (oncology, neurology, respiratory disorders, metabolic disorders/endocrinology, cardiovascular system disorders, dermatology, gastrointestinal system disorders, immunological disorders, infectious diseases, psychiatry, ophthalmology, hematology, genitourinary & women's health, and other therapeutic areas).

#### Key Players:

Some of the prominent players are Thermo Fisher Scientific Inc. (US), Novo Holdings A/S (Denmark), Marken (UPS) (US), Eurofins Scientific (Luxembourg), Piramal Group (India), Almac Group (UK), Novo Holdings A/S (Denmark), Marken (UPS) (US), PCI Pharma Services (US), and Sharp Services LLC (US), and others. These players are increasingly focusing on product launches and enhancements, investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, sales contracts, and alliances to strengthen their presence in the global market.

#### Top 3 Companies

##### Thermo Fisher Scientific

Thermo Fisher Scientific is a global leader in science and technology, specializing in high-end analytical instruments, laboratory equipment, consumables, reagents, software, and services that support scientific research, discovery, diagnostics, and analysis. The company operates through four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Thermo Fisher's presence in the clinical trial supplies market is anchored through its subsidiary PPD, which falls under the Laboratory Products & Biopharma Services segment. The company delivers a wide range of solutions through its prominent brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

## Sharp Services LLC

Sharp Services is a global provider of contract packaging and clinical trial supply solutions, serving the pharmaceutical, biotechnology, and life sciences industries. The company delivers end-to-end clinical trial services including GMP-compliant primary and secondary packaging, multi-language labeling, blinding services, cold chain logistics, Just-in-Time (JIT) labeling, and global storage and distribution. Sharp supports both clinical and commercial needs while ensuring regulatory compliance and operational flexibility. Headquartered in the United States, Sharp maintains GMP-certified facilities in the U.S. and the U.K., with operations extending across North America and Europe. Its key subsidiaries include Sharp Laboratories of America, Inc. (SLA), Sharp Hong Kong Limited (SHK), Sharp Manufacturing (Thailand) Co., Ltd. (SMTL), and Sharp Corporation of Australia Pty. Ltd. (SCA).

## Parexel International

Parexel International is a leading contract research organization (CRO) that offers comprehensive drug development and regulatory services to pharmaceutical, biotech, and medical device companies. Its core business segment, Clinical Research Services (CRS), encompasses full-spectrum clinical trial management from Phase I to Phase IV, along with biostatistics, pharmacovigilance, data management, regulatory affairs, market access consulting, observational studies, and clinical logistics. Headquartered in the U.S., Parexel has a strong international footprint, with 85 offices across 52 countries. Notable subsidiaries include Parexel International S.A. (Argentina), Parexel Belgium SPRL, Parexel International, LLC (U.S.), Parexel International (Canada) Ltd., Parexel China Ding Hui Co., Ltd., Parexel International GmbH (Germany), Parexel International Limited (UK), and Parexel International Inc. (Japan).

## Contents

### **1 INTRODUCTION**

- 1.1 MARKET DEFINITION
- 1.2 INCLUSIONS & EXCLUSIONS
- 1.3 STAKEHOLDERS

### **2 EXECUTIVE SUMMARY**

### **3 MARKET OVERVIEW**

- 3.1 INTRODUCTION
- 3.2 MARKET DYNAMICS
  - 3.2.1 DRIVERS
    - 3.2.1.1 Growth in clinical trials & drug development
    - 3.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies
    - 3.2.1.3 Rising demand for personalized medicine and biologics
  - 3.2.2 RESTRAINTS
    - 3.2.2.1 High costs associated with clinical trial supplies
  - 3.2.3 OPPORTUNITIES
    - 3.2.3.1 Rise in decentralized and virtual trials
    - 3.2.3.2 Integration of digital technologies in supply chain management
  - 3.2.4 CHALLENGES
    - 3.2.4.1 Supply chain disruptions and drug shortages
- 3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 3.4 VALUE CHAIN ANALYSIS
- 3.5 ECOSYSTEM ANALYSIS
  - 3.5.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS
  - 3.5.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS
  - 3.5.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS
  - 3.5.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES
- 3.6 TECHNOLOGY ANALYSIS
  - 3.6.1 KEY TECHNOLOGIES
    - 3.6.1.1 Serialization & track-and-trace technologies
    - 3.6.1.2 Interactive response technology (IRT/IVR/IWR)
    - 3.6.1.3 Cold chain & temperature monitoring solutions
  - 3.6.2 COMPLEMENTARY TECHNOLOGIES

- 3.6.2.1 Artificial intelligence (AI) & machine learning (ML)
- 3.6.2.2 Blockchain for supply chain transparency
- 3.6.3 ADJACENT TECHNOLOGIES
  - 3.6.3.1 Cryopreservation & advanced storage technologies
  - 3.6.3.2 Advanced robotics in warehousing & distribution
- 3.7 KEY CONFERENCES AND EVENTS, 2025–2026
- 3.8 PORTER'S FIVE FORCES ANALYSIS
  - 3.8.1 THREAT OF NEW ENTRANTS
  - 3.8.2 BARGAINING POWER OF SUPPLIERS
  - 3.8.3 BARGAINING POWER OF BUYERS
  - 3.8.4 THREAT OF SUBSTITUTES
  - 3.8.5 INTENSITY OF COMPETITIVE RIVALRY
- 3.9 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL SUPPLIES MARKET
  - 3.9.1 INTRODUCTION
  - 3.9.2 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL SUPPLIES ECOSYSTEM

## **4 COMPETITIVE LANDSCAPE**

- 4.1 INTRODUCTION
- 4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  - 4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET
- 4.3 REVENUE ANALYSIS, 2020–2024
- 4.4 MARKET SHARE ANALYSIS, 2024
- 4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  - 4.5.1 STARS
  - 4.5.2 EMERGING LEADERS
  - 4.5.3 PERVASIVE PLAYERS
  - 4.5.4 PARTICIPANTS
  - 4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - 4.5.5.1 Company footprint
    - 4.5.5.2 Region footprint
    - 4.5.5.3 Service footprint
    - 4.5.5.4 Type footprint
    - 4.5.5.5 End-user footprint
- 4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 4.6.1 PROGRESSIVE COMPANIES
  - 4.6.2 RESPONSIVE COMPANIES
  - 4.6.3 DYNAMIC COMPANIES

#### 4.6.4 STARTING BLOCKS

#### 4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

##### 4.6.5.1 Detailed list of key startups/SMEs

##### 4.6.5.2 Competitive benchmarking of key startups/SMEs

#### 4.7 COMPANY VALUATION & FINANCIAL METRICS

##### 4.7.1 COMPANY VALUATION

##### 4.7.2 FINANCIAL METRICS

#### 4.8 BRAND/SERVICE COMPARISON

#### 4.9 COMPETITIVE SCENARIO

##### 4.9.1 DEALS

##### 4.9.2 EXPANSIONS

### **5 COMPANY PROFILES**

#### 5.1 KEY PLAYERS

##### 5.1.1 THERMO FISHER SCIENTIFIC INC.

###### 5.1.1.1 Business overview

###### 5.1.1.2 Services offered

###### 5.1.1.3 Recent developments

###### 5.1.1.3.1 Service launches

###### 5.1.1.3.2 Deals

###### 5.1.1.3.3 Expansions

###### 5.1.1.4 MnM view

###### 5.1.1.4.1 Right to win

###### 5.1.1.4.2 Strategic choices

###### 5.1.1.4.3 Weaknesses & competitive threats

##### 5.1.2 NOVO HOLDINGS A/S

###### 5.1.2.1 Business overview

###### 5.1.2.2 Services offered

###### 5.1.2.3 Recent developments

###### 5.1.2.3.1 Deals

###### 5.1.2.3.2 Expansions

###### 5.1.2.4 MnM view

###### 5.1.2.4.1 Right to win

###### 5.1.2.4.2 Strategic choices

###### 5.1.2.4.3 Weaknesses & competitive threats

##### 5.1.3 UNITED PARCEL SERVICE OF AMERICA, INC.

###### 5.1.3.1 Business overview

###### 5.1.3.2 Services offered

- 5.1.3.3 MnM view
  - 5.1.3.3.1 Right to win
  - 5.1.3.3.2 Strategic choices
  - 5.1.3.3.3 Weaknesses & competitive threats
- 5.1.4 EUROFINS SCIENTIFIC
  - 5.1.4.1 Business overview
  - 5.1.4.2 Services offered
  - 5.1.4.3 MnM view
    - 5.1.4.3.1 Right to win
    - 5.1.4.3.2 Strategic choices
    - 5.1.4.3.3 Weaknesses & competitive threats
- 5.1.5 PIRAMAL PHARMA LIMITED
  - 5.1.5.1 Business overview
  - 5.1.5.2 Services offered
  - 5.1.5.3 MnM view
    - 5.1.5.3.1 Right to win
    - 5.1.5.3.2 Strategic choices
    - 5.1.5.3.3 Weaknesses & competitive threats
- 5.1.6 IQVIA
  - 5.1.6.1 Business overview
  - 5.1.6.2 Services offered
- 5.1.7 ICON PLC
  - 5.1.7.1 Business overview
  - 5.1.7.2 Services offered
  - 5.1.7.3 Recent developments
    - 5.1.7.3.1 Deals
- 5.1.8 LONZA
  - 5.1.8.1 Business overview
  - 5.1.8.2 Services offered
  - 5.1.8.3 Recent developments
    - 5.1.8.3.1 Deals
- 5.1.9 UNIPHAR GROUP PLC
  - 5.1.9.1 Business overview
  - 5.1.9.2 Services offered
- 5.1.10 ALMAC GROUP
  - 5.1.10.1 Business overview
  - 5.1.10.2 Services offered
  - 5.1.10.3 Recent developments
    - 5.1.10.3.1 Expansions

**5.1.11 SHARP SERVICES, LLC**

5.1.11.1 Business overview

5.1.11.2 Services offered

**5.1.12 PCI PHARMA SERVICES**

5.1.12.1 Business overview

5.1.12.2 Services offered

5.1.12.3 Recent developments

5.1.12.3.1 Expansions

**5.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION**

5.1.13.1 Business overview

5.1.13.2 Services offered

5.1.13.3 Recent developments

5.1.13.3.1 Deals

**5.1.14 BIOCAIR**

5.1.14.1 Business overview

5.1.14.2 Services offered

**5.2 OTHER PLAYERS**

5.2.1 CENCORA, INC.

5.2.2 CLINIGEN LIMITED

5.2.3 KLIFO

5.2.4 IPS PHARMA

5.2.5 COREX LOGISTICS LIMITED

5.2.6 OCT GROUP LLC

5.2.7 MYONEX

5.2.8 INCEPTUA GROUP

5.2.9 ANCILLARE, LP

5.2.10 ADALLEN PHARMA

5.2.11 CLINICAL SERVICES INTERNATIONAL (CSI)

5.2.12 NUVISAN GMBH

5.2.13 AENOVA HOLDING GMBH

**6 APPENDIX****6.1 RESEARCH METHODOLOGY**

6.1.1 RESEARCH DATA

6.1.1.1 Secondary data

6.1.1.2 Primary research

6.1.2 RESEARCH ASSUMPTIONS

6.1.3 RESEARCH LIMITATIONS

6.1.4 RISK ANALYSIS  
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY  
6.3 AUTHOR DETAILS

## List Of Tables

### LIST OF TABLES

TABLE 1 CLINICAL TRIAL SUPPLIES MARKET: PRODUCT MANUFACTURERS

TABLE 2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS

TABLE 3 CLINICAL TRIAL SUPPLIES MARKET: END USERS

TABLE 4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES

TABLE 5 CLINICAL TRIAL SUPPLIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 6 CLINICAL TRIAL SUPPLIES MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 7 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET

TABLE 8 CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION

TABLE 9 CLINICAL TRIALS SUPPLIES MARKET: REGION FOOTPRINT

TABLE 10 CLINICAL TRIAL SUPPLIES MARKET: SERVICE FOOTPRINT

TABLE 11 CLINICAL TRIAL SUPPLIES MARKET: TYPE FOOTPRINT

TABLE 12 CLINICAL TRIAL SUPPLIES MARKET: END-USER FOOTPRINT

TABLE 13 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 14 CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 15 CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2021–MARCH 2025

TABLE 16 CLINICAL TRIAL SUPPLIES MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025

TABLE 17 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 18 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED

TABLE 19 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES, JANUARY 2021–MARCH 2025

TABLE 20 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025

TABLE 21 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–MARCH 2025

TABLE 22 NOVO HOLDINGS A/S: COMPANY OVERVIEW

TABLE 23 NOVO HOLDINGS A/S: SERVICES OFFERED

TABLE 24 NOVO HOLDINGS A/S: DEALS, JANUARY 2021–MARCH 2025

TABLE 25 NOVO HOLDINGS A/S: EXPANSIONS, JANUARY 2021–MARCH 2025

TABLE 26 UNITED PARCEL SERVICE OF AMERICA, INC.: COMPANY OVERVIEW

TABLE 27 UNITED PARCEL SERVICE OF AMERICA, INC.: SERVICES OFFERED

TABLE 28 EUROFINS SCIENTIFIC: COMPANY OVERVIEW

TABLE 29 EUROFINS SCIENTIFIC: SERVICES OFFERED

TABLE 30 PIRAMAL PHARMA LIMITED: COMPANY OVERVIEW

TABLE 31 PIRAMAL PHARMA LIMITED: SERVICES OFFERED

TABLE 32 IQVIA: COMPANY OVERVIEW

TABLE 33 IQVIA: SERVICES OFFERED

TABLE 34 ICON PLC: COMPANY OVERVIEW

TABLE 35 ICON PLC: SERVICES OFFERED

TABLE 36 ICON PLC: DEALS, JANUARY 2021–MARCH 2025

TABLE 37 LONZA: COMPANY OVERVIEW

TABLE 38 LONZA: SERVICES OFFERED

TABLE 39 LONZA: DEALS, JANUARY 2021–MARCH 2025

TABLE 40 UNIPHAR GROUP PLC: COMPANY OVERVIEW

TABLE 41 UNIPHAR GROUP PLC: SERVICES OFFERED

TABLE 42 ALMAC GROUP: COMPANY OVERVIEW

TABLE 43 ALMAC GROUP: SERVICES OFFERED

TABLE 44 ALMAC GROUP: EXPANSIONS, JANUARY 2021–MARCH 2025

TABLE 45 SHARP SERVICES, LLC: COMPANY OVERVIEW

TABLE 46 SHARP SERVICES, LLC: SERVICES OFFERED

TABLE 47 PCI PHARMA SERVICES: COMPANY OVERVIEW

TABLE 48 PCI PHARMA SERVICES: SERVICES OFFERED

TABLE 49 PCI PHARMA SERVICES: EXPANSIONS, JANUARY 2021–MARCH 2025

TABLE 50 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW

TABLE 51 PAREXEL INTERNATIONAL (MA) CORPORATION.: SERVICES OFFERED

TABLE 52 PAREXEL INTERNATIONAL (MA) CORPORATION: DEALS, JANUARY 2021–MARCH 2025

TABLE 53 BIOCAIR: COMPANY OVERVIEW

TABLE 54 BIOCAIR: SERVICES OFFERED

TABLE 55 CENCORA, INC.: COMPANY OVERVIEW

TABLE 56 CLINIGEN LIMITED: COMPANY OVERVIEW

TABLE 57 KLIFO: COMPANY OVERVIEW

TABLE 58 IPS PHARMA: COMPANY OVERVIEW

TABLE 59 COREX LOGISTICS LIMITED: COMPANY OVERVIEW

TABLE 60 OCT GROUP LLC: COMPANY OVERVIEW

TABLE 61 MYONEX: COMPANY OVERVIEW

TABLE 62 INCEPTUA GROUP: COMPANY OVERVIEW

TABLE 63 ANCILLARE, LP: COMPANY OVERVIEW

TABLE 64 ADALLEN PHARMA: COMPANY OVERVIEW

TABLE 65 CLINICAL SERVICES INTERNATIONAL (CSI): COMPANY OVERVIEW

TABLE 66 NUVISAN GMBH: COMPANY OVERVIEW

TABLE 67 AENOVA HOLDING GMBH: COMPANY OVERVIEW

TABLE 68 CLINICAL TRIAL SUPPLIES MARKET: RISK ASSESSMENT ANALYSIS

## List Of Figures

### LIST OF FIGURES

FIGURE 1 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 2 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 3 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION)

FIGURE 4 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2025 VS. 2030 (USD MILLION)

FIGURE 5 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 6 GEOGRAPHIC SNAPSHOT OF CLINICAL TRIAL SUPPLIES MARKET, 2025?2030

FIGURE 7 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 8 NUMBER OF CLINICAL TRIALS PER YEAR, 2004–2024

FIGURE 9 CLINICAL TRIAL SUPPLIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 10 CLINICAL TRIAL SUPPLIES MARKET: VALUE CHAIN ANALYSIS

FIGURE 11 CLINICAL TRIAL SUPPLIES MARKET: ECOSYSTEM ANALYSIS

FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 13 IMPACT OF AI ON CLINICAL TRIAL SUPPLIES ECOSYSTEM

FIGURE 14 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET, 2020–2024 (USD MILLION)

FIGURE 15 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET (2024)

FIGURE 16 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 17 CLINICAL TRIAL SUPPLIES MARKET: COMPANY FOOTPRINT

FIGURE 18 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 19 EV/EBITDA OF KEY VENDORS

FIGURE 20 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 21 CLINICAL TRIAL SUPPLIES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS

FIGURE 22 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 23 NOVO HOLDINGS A/S: COMPANY SNAPSHOT

FIGURE 24 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT

FIGURE 25 PIRAMAL PHARMA LIMITED: COMPANY SNAPSHOT

FIGURE 26 IQVIA: COMPANY SNAPSHOT

FIGURE 27 ICON PLC: COMPANY SNAPSHOT

FIGURE 28 LONZA: COMPANY SNAPSHOT

FIGURE 29 UNIPHAR GROUP PLC: COMPANY SNAPSHOT

FIGURE 30 CLINICAL TRIAL SUPPLIES MARKET: RESEARCH DESIGN

## I would like to order

Product name: Clinical Trial Supplies - Company Evaluation Report, 2025

Product link: <https://marketpublishers.com/r/CCA5A035E715EN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCA5A035E715EN.html>